EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled

Thursday, December 13, 2018 1 min read

Key Takeaway: EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled